WO2001027619A1 - Methode de detection d'un agent chimique exogene de perturbation endocrine et appareil de detection - Google Patents
Methode de detection d'un agent chimique exogene de perturbation endocrine et appareil de detection Download PDFInfo
- Publication number
- WO2001027619A1 WO2001027619A1 PCT/JP2000/001813 JP0001813W WO0127619A1 WO 2001027619 A1 WO2001027619 A1 WO 2001027619A1 JP 0001813 W JP0001813 W JP 0001813W WO 0127619 A1 WO0127619 A1 WO 0127619A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hormone
- detection
- antibody
- female hormone
- immobilized
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
Definitions
- the present invention relates to a method and an apparatus for detecting an exogenous endocrine disrupting substance, and more particularly, to a method and an apparatus for detecting an exogenous endocrine disrupting substance called an environmental hormone with high sensitivity and easy.
- exogenous endocrine disruptors so-called environmental hormones, which have become a social problem, are thought to adversely affect living organisms by disrupting the action of natural hormones in the body.
- certain perturbing mechanisms of female hormone action have been proposed as follows.
- Female hormone action is usually triggered in vivo by the binding of female hormones to the corresponding hormone receptors.
- the conjugate of the hormone and its receptor dimerizes and binds to specific sequences of DNA. This initiates the transcription of genes required for hormonal action, resulting in physiological effects.
- the exogenous endocrine disrupting substance disrupts the above hormonal action by binding to a receptor instead of a natural female hormone.
- the present inventors have conducted intensive studies and have found that many chemicals suspected of being environmental hormones have a similar effect to female hormones.
- the present inventors have conducted intensive studies and have found that many chemicals suspected of being environmental hormones have a similar effect to female hormones.
- the present inventors have found that high sensitivity can be detected easily and the present invention has been completed.
- the present invention that achieves the above objects is a method for detecting the presence of an exogenous endocrine disrupting substance in a sample, comprising using an immobilized female hormone receptor and a fluorescently labeled female hormone, Perform a competitive binding reaction between a known amount of the fluorescently labeled female hormone and a known amount of the exogenous endocrine disruptor in the sample with respect to the known amount of the immobilized female hormone receptor.
- the present invention relates to a method for detecting an endogenous endocrine disrupting substance, which comprises measuring the fluorescence intensity of labeled fluorescence of a bound female hormone.
- a certain concentration of a fluorescently labeled female hormone is introduced into a detection container filled with an immobilized female hormone receptor. Fluorescence intensity detected when the detected value F.
- the fluorescence intensity detected when the same concentration of fluorescently labeled female hormone as above mixed with the sample to be tested is introduced into the above detection container is the detection value F!
- the detection value F i becomes the detection value F 0 If smaller, it is characterized in that the endogenous endocrine disrupting substance is present in the sample to be tested. Thereby, qualitative detection can be easily performed.
- the method for detecting an endogenous endocrine disrupting substance is a method for detecting when a certain concentration of a fluorescently labeled female hormone is introduced into a detection container filled with an immobilized female hormone receptor. Fluorescence intensity detected F. To be tested The fluorescence intensity detected when the same concentration of fluorescently labeled female hormone as above mixed with the sample is introduced into the above detection container is the detection value F! And the detection value F i and the detection value F. And calculating the amount of the exogenous endocrine disrupting substance present in the sample to be tested by a calibration curve prepared in advance. This enables quantitative detection.
- the present invention also shows a method for detecting the endogenous endocrine disrupting substance, wherein the female hormone receptor is an estrogen receptor.
- the female hormone receptor is an estrogen receptor.
- the present invention also shows the method for detecting an endogenous endocrine disrupting substance, wherein the detection container is a cell having a capacity of 100 mm 3 or less. By using such a cell, detection can be performed more quickly with a small amount of immobilized female hormone receptor.
- the present invention further provides a method for detecting an endogenous endocrine disrupting substance as described above, wherein the detection container is of a flow type so that the sample can continuously contact the immobilized female hormone receptor. If the detection container is of a flow type, even if there is only a very small amount of an exogenous endocrine disrupting substance in the sample, the disturbing substance is accumulated in the immobilized female hormone receptor in the detection container, thereby further increasing the detection limit. Can be improved.
- the present invention that achieves the above objects also includes a detection container filled with an immobilized female hormone receptor, a light source that excites the inside of the detection container, and a detector that detects the fluorescence intensity in the detection container after the excitation.
- This is a device for detecting an endogenous endocrine disrupting substance, which is used in combination with a fluorescently labeled female hormone.
- the present invention also provides an apparatus for detecting the endogenous endocrine disrupting substance, wherein the female hormone receptor is an estrogen receptor.
- the present invention also provides the exogenous endocrine secretion, wherein the detection container is a cell having a volume of 100 mm 3 or less. 3 shows a device for detecting a disturbing substance.
- the present invention further provides a device for detecting an endogenous endocrine disrupting substance as described above, wherein the detection container is of a flow type so that the sample can continuously contact the immobilized female hormone receptor.
- the present inventor further combines an immobilized female hormone and an anti-hormone antibody against the female hormone from the same viewpoint as in the above-described method using a female hormone receptor, and comprises the above-mentioned anti-hormone in a sample to be tested.
- An antibody is introduced to cause an antigen-antibody reaction between the environmental hormone and the anti-hormonal antibody, and then the reaction mixture is contacted with an immobilized female hormone to immobilize unreacted anti-hormone antibodies present in the reaction mixture.
- the presence or absence of environmental hormones in the sample can be detected with high sensitivity and ease As a result of earnest study that they can be detected, they have further studied and completed the present invention.
- a second invention for solving the above-mentioned objects is a method for detecting the presence of an exogenous endocrine disrupting substance in a sample, which comprises immobilizing a female hormone and an anti-hormone antibody against the female hormone. A known amount of anti-hormone antibody is introduced into the sample, and subjected to an antigen-antibody reaction with an exogenous endocrine disrupting substance of unknown unknown.
- a reaction mixture of the anti-hormone antibody and the sample is mixed with a known amount of Exogenous endocrine secretion characterized by contacting with an immobilized female hormone and detecting the amount of antihormonal antibody bound to the immobilized female hormone by measuring the fluorescence intensity of the labeled fluorescence bound to the anti-hormone antibody.
- the anti-hormone antibody is a fluorescent-labeled anti-hormone antibody, and the amount of the anti-hormone antibody bound to the immobilized female hormone. Is detected by measuring the fluorescence intensity of the labeled fluorescence of the fluorescently labeled anti-hormone antibody.
- the anti-hormone antibody is a non-labeled primary antibody, and the anti-hormone bound to immobilized female hormone is used.
- the amount of Lumon antibody was determined by using a fluorescent-labeled anti-primary antibody that specifically binds to the primary antibody as the secondary antibody, and allowing the secondary antibody to specifically bind to the primary antibody bound to the immobilized female hormone. Detection is performed by measuring the fluorescence intensity of the labeled fluorescence of the bound secondary antibody.
- the method for detecting an endogenous endocrine disrupting substance according to the second invention comprises: Detection value F.
- the detection value is the fluorescence intensity detected when the same concentration of antihormonal antibody as above mixed with the sample to be tested is introduced into the detection container, and the detection value is the detection value F. If smaller than the above, it is characterized in that the endogenous endocrine disrupting substance is present in the sample to be tested.
- the method for detecting an endogenous endocrine disrupting substance according to the second invention is a method for detecting a fluorescence intensity detected when a certain concentration of an anti-hormone antibody is introduced into a detection container filled with immobilized female hormone.
- the detected intensity is defined as F o, and the detected intensity is the fluorescence intensity detected when the same concentration of the anti-hormone antibody mixed with the sample to be tested is introduced into the detection container.
- calculating the amount of the exogenous endocrine disrupting substance present in the sample to be tested by a calibration curve prepared in advance.
- the present invention also shows the method for detecting an endogenous endocrine disrupting substance, wherein the detection container is a cell having a capacity of 100 mm 3 or less. By using such a cell, it becomes possible to detect the difference in the fluorescence intensity between small samples.
- the present invention further provides a method for detecting an endogenous endocrine disrupting substance as described above, wherein the detection container is a complete mouth so that the sample can continuously contact the immobilized female hormone receptor.
- the above objects also include a detection container filled with immobilized female hormone, a light source that excites the inside of the detection container, and a detector that detects the fluorescence intensity in the detection container after the excitation. It can also be achieved by a device for detecting an endogenous endocrine disrupting substance, which is characterized by being used in combination with an antihormone antibody against a female hormone.
- the above objects are further achieved by a detection container filled with immobilized female hormone, And a detector for detecting the fluorescence intensity in the detection container after the excitation, and an anti-hormone primary antibody against the female hormone and a fluorescently labeled secondary antibody that specifically binds to the anti-hormone antibody
- a detection container filled with immobilized female hormone And a detector for detecting the fluorescence intensity in the detection container after the excitation, and an anti-hormone primary antibody against the female hormone and a fluorescently labeled secondary antibody that specifically binds to the anti-hormone antibody
- an apparatus for detecting an exogenous endocrine disrupting substance which is characterized by being used in combination with the above.
- FIG. 1 is a drawing schematically showing an apparatus for detecting an endogenous endocrine disrupting substance of the present invention.
- FIG. 2 is a graph showing fluorescence accumulation detection when a female hormone sample is bound to an estrogen receptor.
- Figure 3 is a graph showing the change in fluorescence intensity due to the coexistence of natural hormones. Natural hormones (A) are 17? -Estradiol, (B) is estriol, and (C) is testosterone.
- FIG. 4 is a graph showing the change in the binding inhibition rate depending on the concentration of various hormones.
- FIG. 5 is a graph showing a change in fluorescence intensity due to the coexistence of a chemical substance.
- the chemical substances are (A) moxifen, (B) bisphenol eight, ( ⁇ ) 0 £ 3, and (D) nonylphenol.
- FIG. 6 is a graph showing the change in the binding inhibition rate depending on the concentration of various chemical substances.
- FIG. 7 is a drawing schematically showing another method and apparatus for detecting an exogenous endocrine disrupting substance of the present invention, wherein (A) shows an example of the apparatus used, and (B) shows a series of steps of the detection operation.
- (C) is a schematic diagram of a change in the vicinity of the antigen-immobilized bead surface in a series of steps of the detection operation.
- FIG. 8 is a graph showing quantitative results of estriol measured in a system in which an antihormone antibody was fluorescently labeled.
- FIG. 9 is a graph showing the quantitative results of estriol and estradiol measured in a system using a fluorescently labeled secondary antibody.
- immobilized female hormone receptor means a female hormonal receptor immobilized on an insoluble carrier.
- estrogen receptor for example, an estrogen receptor, a gestagen receptor and the like can be used.
- Estrogen receptors are preferred because they can bind a wide variety of endogenous endocrine disruptors.
- estrogen receptor means estrogen receptor. It is also called a receptor, and it is located in the target cell nucleus of estrogen in the body and binds to estrogen to mediate activation of protein synthesis dependent on specific genes.
- an insoluble carrier for immobilizing such a female hormone receptor for example, immobilizing beads made of polymethylmethacrylic acid, glass, etc., and fine particles such as calcium alginate particles can be used. It is not particularly limited to these, and various shapes and materials can be used. Of these, beads or fine particles are preferable, and beads or fine particles having an average particle diameter of about 50 to 100 / m are particularly preferable.
- the method for immobilizing the female hormone receptor on such an insoluble carrier is not particularly limited.
- the female hormone receptor can be bound using a natural adsorption method, an ionic bonding method, a covalent bonding method, or the like.
- any female hormone used to obtain the standard of the fluorescence intensity can be used as long as it has an estrus effect.
- Steroid hormones such as estradiol, estrone, estriol, equilin, and elekinin or Its metabolites and chemical derivatives thereof, for example, homoestrone, ethinylestradiol, docinoleic acid, synthetic estrogen and the like can be mentioned.
- Fluorescent labeling of these female hormones can be performed by conventional means, and fluorescent dyes for labeling include CY5, fluorescein isothiosinate, tetramethylrhodamine sothiosineate, and the like.
- the present invention relates to various samples in the environment in which the presence of an exogenous endocrine disruptor is to be tested, i.e., if the disruptor is present in the sample to be tested, it binds to the female hormone receptor.
- This phenomenon is intended to be used to detect such a disturbing substance.
- the fluorescence intensity when a certain concentration of fluorescently labeled female hormone is bound to the female hormone receptor is determined (this value is referred to as a detection value F).
- the fluorescence intensity when the same concentration of the fluorescently labeled female hormone mixed with the sample to be tested is bound to the female hormone receptor is measured (this value is used as the detection value). ).
- the detected value is the detected value F. If it is smaller than (Fi ⁇ F.), it can be determined that an exogenous endocrine disrupting substance is present in the sample to be tested.
- the present invention in order to measure the labeled fluorescence of the fluorescently labeled female hormone bound to the immobilized female hormone receptor, it is quick to use a detection container having the immobilized female hormone inside. It is preferable for performing the measurement.
- the detection container must hold the immobilized female hormone receptor inside and do not inhibit the detection of fluorescence from the fluorescently labeled female hormone bound to the receptor, for example, transparent glass or transparent plastic. Etc.
- the detection vessel may be shaped so that the bottom is closed and the sample to be introduced does not flow out (in this case, each measurement of the fluorescence intensity is performed in a batch format), but it is immobilized on the open bottom.
- the immobilized receptor is held and constrained so that the immobilized receptor can pass through it to a predetermined site in the open container (see
- the sample can be continuously introduced into the detection container, so that even if the sample contains a very small amount of the target substance bound to the receptor, the target substance can be detected. It is preferable because it accumulates and concentrates in the container, and as a result, the detection limit concentration of the target substance is improved.
- the method of holding the immobilized receiver in the flow-type detection container is not limited to the above-described method using a holding material such as a screen. Any method may be adopted in which a lump having liquid permeability is used as the carrier to be immobilized and the lump is arranged so as to close the flow path cross section of the detection container.
- the detection container is preferably in the form of a micro cell so that a very small difference in fluorescence intensity can be detected even between a small amount of samples.
- Small cell for example 1 0 0 mm 3 or less, it is desirable in particular having a volume of 2 0 ⁇ 7 0 mm 3.
- the fluorescence intensity is detected by a detector, and the fluorescence generated when the labeled fluorescence on the female hormone captured by the receptor is excited by laser light from an appropriate light source, irradiation with a mercury lamp or the like. Since the present invention directly utilizes the ability of an endogenous endocrine disrupting substance to bind to a female hormone receptor, the present invention is applicable to immunoassays and the like, which indirectly measure antibodies of a receptor that did not bind to the disrupting substance. In comparison, the detection sensitivity is significantly improved, and the detection is performed by measuring the fluorescence intensity. Therefore, the operation is extremely easy as compared with the conventional method using radiation or recombinant yeast.
- exogenous endocrine disrupting substances so-called environmental hormones, which are known to bind to hormone receptors in place of natural female hormones and disrupt hormonal action in the body, with high sensitivity. , And can be easily detected.
- the fluorescence intensity F in the case of only a fluorescently labeled female hormone is used. Fluorescence intensity in the case of a mixture of a sample, a sample, and the above-mentioned female hormone F! Compared with F, is F. If the difference is smaller, that is, if the difference represented by the formula 1 is positive, it is determined that an exogenous endocrine disrupting substance is present in the sample, which is a so-called qualitative test.
- the female hormone is immobilized on an insoluble carrier.
- the insoluble carrier and the female hormone used the same as those described above can be exemplified.
- the method of immobilizing the female hormone on the carrier is not particularly limited as long as the method does not inactivate the hormone.
- a hormone can be directly bound to a carrier using a natural adsorption method, an ionic bonding method, a covalent bonding method, or the like. It is also possible to connect indirectly via a link. For example, it is desirable to introduce a functional group into a site that does not affect the activity of the hormone and bind via a covalent bond, and to adopt a mode in which a long-chain spacer is provided.
- a method of diazotizing a carrier having an aromatic amino group and diazo coupling a chemical substance serving as an antigen such as a hormone examples include a method in which a polysaccharide such as cephalose is activated with BrCN and covalently bonded to an amino group of a chemical substance such as a hormone having an amino group.
- formone can be bound to a protein by a chemical bond, and this conjugate can be further immobilized on a carrier.
- a conjugate of a hormone and a protein can be directly bonded to a carrier using a natural adsorption method, an ionic bonding method, a covalent bonding method, or the like. It is also possible to immobilize via a spacer, such as a chemical, eg glutaraldehyde bridge.
- a fluorescently labeled anti-hormone antibody against the female hormone used is prepared separately.
- the antibody may belong to any class of immunoglobulin derived from various animals, and may be a commercially available antibody, or an antibody produced by stimulating an appropriate immune system with the female hormone.
- a separately prepared antibody having high specificity for female hormones may be used.
- monoclonal antibodies For example, anti-estradiol antibodies are available from Biodesign, Biospec, Fiard, and Cortex Biochemistry in the United States, and anti-estriol antibodies are available from BioStride, etc. is there. Fluorescent labeling of such an antibody can be performed by conventional means, and examples of the fluorescent dye to be used are the same as those described above.
- anti-hormone antibodies against female hormones are not fluorescently labeled and used as the primary antibody, and an antibody (anti-primary antibody antibody) that specifically binds to this primary antibody is prepared separately.
- an antibody anti-primary antibody antibody
- This can be used as a secondary antibody after fluorescent labeling.
- the fluorescent-labeled secondary antibody specifically binds to the anti-hormonal antibody (primary antibody) bound to the immobilized female hormone, the immobilization is performed in the same manner as in the above embodiment using the fluorescent-labeled anti-hormone antibody.
- Anti-hormonal antibodies bound to female hormones can be identified by fluorescent labeling.
- the second invention is directed to an anti-hormone antibody against the female hormone described above when various exogenous endocrine disrupting substances are to be tested in the environment to be tested in the environment, that is, when the perturbing substance is present in the sample to be tested.
- An attempt is made to detect the disturbing substance by utilizing a phenomenon of binding to the substance.
- a certain concentration of anti-hormone antibody is immobilized as described above. Measure the fluorescence intensity when bound to female hormones (this value is referred to as detection value F).
- the sample to be tested is contacted with the same concentration of anti-hormone antibody as above, and then the contact mixture is contacted with the above-mentioned immobilized female hormone, and the fluorescence intensity of the anti-hormone antibody bound to the immobilized female hormone is measured.
- This value is referred to as a detected value F i).
- an exogenous endocrine disrupting substance is present in the sample, a part of the antihormonal antibody binds to the exogenous endocrine disrupting substance at the first contact with the sample, and the exogenous endocrine disrupting substance is bound.
- the anti-hormone antibody bound to the substance will no longer attempt to bind to the immobilized female hormone in subsequent contact with the immobilized female hormone, and will remain in the reaction mixture in a free state.
- Value F! This is shown as a decrease in the fluorescence intensity at. Therefore, it can be determined that the detection value is small if (F! F o endocrine disruptors are present in the sample to be the test compared with the detected value F Q.
- the second invention as in the first invention, it is preferable to use a detection container having an immobilized female hormone therein for performing a rapid measurement.
- a detection container having an immobilized female hormone therein for performing a rapid measurement.
- those similar to those described in the first invention can be preferably exemplified, except that the inside held therein is an immobilized female hormone and an immobilized female hormone receptor.
- the method for detecting fluorescence is the same as described above.
- the second invention is a method for indirectly measuring an exogenous endocrine disrupting substance by assaying an amount of an antibody that did not bind to the exogenous endocrine disrupting substance, but immobilizing the unbound antibody on a carrier.
- an antigen male hormone
- it can be accumulated on the immobilized carrier, so that the detection sensitivity is remarkably improved. Since the detection is performed, the operation is extremely easy as compared with the conventional method using radiation or recombinant yeast.
- exogenous endocrine disrupting substances which are known to disturb the hormonal action in the body by binding to hormone receptors instead of natural female hormones, so-called environmental hormones, with high sensitivity. , And can be easily detected.
- the second invention is also based on a qualitative test.However, by preparing a calibration curve in advance using a known concentration of an exogenous endocrine disrupting substance as described above, An exogenous endocrine disrupting substance contained in the sample can be quantified.
- the method and the device for detecting an endogenous endocrine disrupting substance according to the first and second inventions described above detect and detect substances having a binding property to a receptor or an antibody irrespective of the type of receptor or antibody in principle.
- the exogenous endocrine disrupting substance that can be quantified and is detectable is not particularly limited, and may include a wide variety of substances.
- estradiol-3-sulfate estradiol-17-glucuronide
- estradiol_3-glucuronide estriol-1-3-sulfate
- estriol-1 Chemical substances such as 17-glucuronide and estriol-1-glucuronide can be exemplified, but, of course, are not limited to these several chemical substances.
- estrogen receptor human estrogen receptor (Pambella, Drive Madison, Wisconsin, United States) was used. 17-estradiol (manufactured by Wako Pure Chemical Industries, Ltd., Japan), Estoriole (manufactured by Wako Pure Chemical Industries, Ltd.) and testosterone (manufactured by Wako Pure Chemical Industries, Ltd.) were used as standard natural hormones.
- the estrogen receptor was immobilized on a carrier (beads) by natural adsorption.
- the beads for immobilization were polymethylmethacrylic acid particles (manufactured by Ganz Chemical Co., Ltd.) having an average particle size of 95 ⁇ m.
- 0.2 g of the beads were placed in a small test tube, and suspended in lml of binding buffer (50 mM Tris HC1, 500 mM KC1, 2 mM DDT, 1 mM EDTA, 10% glycerol, pH 7.8). .
- binding buffer 50 mM Tris HC1, 500 mM KC1, 2 mM DDT, 1 mM EDTA, 10% glycerol, pH 7.8.
- serum albumin 1001 was added to a final concentration of lmg / ml.
- a bead prepared by adding only serum albumin to the bead was prepared in the same manner.
- a powder sample of 17 serum radio albumin (manufactured by Sigma, supra) was dissolved in a binding buffer to a concentration of lmg / ml.
- a fluorescent dye CY5 having an absorption wavelength at 650 nm was used in consideration of the absorption wavelength of steroid hormones and the like.
- CY5 labeling kit (Amersham Life Sciences, Arlington Heights, Illinois, USA) was used to apply this fluorescent dye.
- the 175-estradiol-peroxyserum albumin to which the fluorescent dye was added and the free fluorescent dye were fractionated by gel filtration chromatography.
- a fluorescently labeled female hormone was obtained in which about 10 fluorescent dyes were added to one molecule of 17-estradiol-pserum albumin.
- a detection device incorporating a flow-type fluorometer manufactured by Sapidine Instrument of Boise, Idaho, USA was used. This detection device is schematically shown in FIG. 1.
- the device can analyze the intermolecular interaction in the liquid phase reaction by measuring the fluorescence intensity.
- the fluorescence intensity is measured in electric signal units by the excitation light source 3 and the detector 4 arranged with the glass cell 1 1.5 mm in diameter and 30 mm in length interposed.
- Bead-shaped immobilized estrogen receptor 2 is installed in glass cell 1
- the glass cell 1 was filled by damping and laminating with a screen S made of a 50-zm nylon mesh.
- the lamination was performed by feeding 0.7 ml of the immobilized estrogen receptor suspension of 6.7 mg / ml at a rate of 1.5 ml / min.
- E2—BSA—CY5 Estradio serum albumin—CY5
- E2—BSA—CY5 alone, or a mixture of E2—BSA—CY5 and a chemical substance or natural hormone
- E2—BSA—CY5 a chemical substance or natural hormone
- the substance is measured as a fluorescence intensity by binding to the immobilized estrogen receptor 2 in the glass cell 1.
- the material remaining between the beads not bound to receptor 2 is eliminated in the direction of arrow b by introducing only buffer at a rate of 1.5 ml / min. Thereafter, the remaining fluorescence intensity was evaluated as the binding amount.
- E2-BSA-CY5 was diluted in the binding buffer to about 400 ng / ml. Note that this concentration was appropriately adjusted in accordance with the fluorescence imparting rate of E2-BSA-CY5.
- An equal volume of a binding buffer in which a known concentration of a natural hormone or a chemical substance was dissolved was added to the diluent, and the mixture was allowed to stand at room temperature for 30 minutes. In the case of a poorly water-soluble substance, it was completely dissolved in dimethyl sulfoxide, appropriately diluted, left to stand, and then subjected to measurement.
- estriol also competitively inhibits the binding of E2-BSA-CY5 to the receptor, as shown in Fig. 3 (B).
- the amount of estriol added was 0 pM, 0.5 pM, 5 pM, 50 pM, and 500 pM, and neither the receptor nor estriol was added.
- testosterone a male hormone, did not inhibit the binding of E2-BSA-CY5 to the receptor at the concentrations measured, as shown in Figure 3 (C). From the graph curve, testosterone was added at 0 pM, 50 pM, 500 pM, 5000 pM, 500,000 pM, and neither receptor nor testosterone was added).
- FIG. 4 shows the relationship between the concentration of the above-mentioned natural hormone and the rate of decrease in the fluorescence intensity.
- the rate of decrease in fluorescence intensity is defined as 100% when no natural hormone is added, and the rate at which binding of E2-BSA-CY5 to the receptor was inhibited by the addition of the hormone (binding inhibition). Rate, unit%).
- 17 -? A concentration range for 10- 13 ⁇ 10- 9 M estradiol, and decrease in fluorescence intensity seen that it is possible to check in a concentration range where 10- 12 ⁇ 10 M of Esutorio Ichiru.
- 17 -? Esutorajio Ichiru is in a concentration range of 10- 13 ⁇ 10- 9 M, and estriol can be detected in a concentration range of 10- I2 ⁇ l 0- 9 M.
- the Bisufue Nord A it it 10- 12 ⁇ : L 0- 9 M, 10- 12 ⁇ : L 0- 9 M, 10- 9 ⁇ : 10- 5 M, can be detected in a concentration range of 10- 8 ⁇ 10- 6 M.
- a chemical substance having a female hormone receptor binding property can be detected simply and with high sensitivity.
- estradiol 3-sulfate estradiol 17-glucuronide
- estradiol 3-ru-glucuronide estradiol 3-ru-glucuronide
- estriol 1-3-s estradiol 3-sulfate, estradiol 17-glucuronide, estradiol 3-ru-glucuronide, estriol 1-3-s
- 17-estradiol manufactured by Wako Pure Chemical Industries
- estriol manufactured by Wako Pure Chemical Industries
- the anti-estradiol antibodies used were those of Biodesign, Biospacific, Fytherald, and Cotex Biochemistry
- the anti-estriol antibodies used were those of Biostride.
- a secondary antibody a specific antibody against the above-mentioned anti-female hormone antibody (Jackson Immuno Research Laboratories, Inc., Pennsylvania, United States).
- estradiol and estriol were performed by the natural adsorption method. Specifically, bovine serum albumin (Sigma, United States) bound to estradiol or estriol was used. 100 micrograms of estriol-conjugated bovine serum albumin is dissolved in 1 ml of physiological saline, and 200 milligrams of polymethylmethacrylic acid particles having an average particle size of 95 / zm (Gantz Chemical Co., Ltd.) Made). Thereafter, shaking was performed for 1 hour to promote natural adsorption. After spontaneous absorption, an additional 100 microliters of bovine serum albumin (100 milligrams / m
- the fluorescent labeling of the anti-estradiol antibody or anti-estriol antibody was performed using a CY5 labeling kit (Amersham Life Sciences, Arlington Heights, Ill., USA). Fluorescently labeled secondary antibodies to these anti-female hormone antibodies were purchased from Jackson Imiuno Research Laboratories, supra.
- the fluorescence intensity is measured using a detection device equipped with a flow-type fluorometer (Sapidin Instrument, Boise, Idaho, USA) as in Experiment I. The procedure was performed in substantially the same manner.
- Fig. 7 shows an outline of the detection method when the anti-hormone antibody is unlabeled (primary antibody) and a fluorescently labeled antibody that specifically binds to the anti-hormone antibody is used as the secondary antibody.
- a detector equipped with a single-ended fluorimeter made by Sapidin Instrument of Boise, Idaho, USA was used as the detector, as shown in Fig. 7 (A).
- Excitation light from an excitation light source (not shown) is incident on female hormone-immobilized beads (antigen-immobilized beads) 1 2 filled in a glass cell 11 by a focusing optical lens 16 arranged in front of 1.
- the fluorescent light excited and emitted by the incident light is directed to a detector (not shown) by the optical lens 16, and the fluorescent light intensity is measured by the detector in electric signal units.
- the female holmon-immobilized beads 12 were filled into the glass cell 11 by laminating by laminating with a screen S installed in the glass cell 11.
- a rotary valve 17 connected to a supply source of beads, a sample, a washing solution, and a fluorescent-labeled secondary antibody is arranged on the upstream side of the glass cell 11, and a syringe bottle arranged on the downstream side. These substances were sequentially supplied into the glass cell by operating in cooperation with a tube (not shown).
- the sample is mixed with a known amount of primary antibody and brought into contact with antigen (female hormone) -immobilized beads (step 1).
- antigen female hormone
- the surplus unreacted primary antibody that has not reacted with the free female hormone contained in the sample reacts with the immobilized antigen on the bead and is captured.
- a sufficient amount of the fluorescent-labeled secondary antibody is flowed into the cell (step 2).
- the fluorescent-labeled secondary antibody specifically reacts with the primary antibody captured by the immobilized antigen, and only an amount corresponding to the amount of the bound primary antibody binds to the immobilized beads.
- Step 3 the washing solution is flushed to remove the unbound fluorescent-labeled secondary antibody from the cell (Step 3), and only the labeled fluorescent substance bound via the secondary antibody to the primary antibody bound to the antigen-immobilized beads is removed.
- the amount of the primary antibody bound to the antigen-immobilized beads can be detected, and the amount of free antigen present in the sample can be determined.
- FIG. 7 (B) shows a typical example of a change in the fluorescence intensity detected in these series of steps.
- Figure 8 shows the results of quantitative determination of estriol in a system labeled with an antihormone antibody
- Figure 9 shows the quantitative results of estriol and estradiol measured in a system with a fluorescently labeled secondary antibody. It shows.
- estriol is added at various concentrations to a fixed concentration of fluorescently labeled antibody
- the rate of decrease in fluorescence intensity detected in the detection vessel is defined as the rate of inhibition of binding to immobilized hormone, and free estriol at that time is used.
- FIG. 7 shows the relationship with the added concentration of.
- the inhibition of binding to immobilized hormone can be measured as a change in fluorescence intensity.
- a detection limit of about 50 to 100 times can be achieved as compared with the case where estriol and estradiol are similarly detected by the conventional enzyme-linked immunosorbent method (ELISA), and the detection method of the present invention has high sensitivity. It was shown to be.
- the method and device for detecting an endogenous endocrine disrupting substance of the present invention can detect and quantify a substance having a binding property to a receptor or antibody regardless of the type of receptor or antibody in principle. It is capable of detecting exogenous endocrine disrupting substances several tens of times more sensitively than conventional methods with the highest sensitivity. Furthermore, the detection of an exogenous endocrine disrupting substance in the present invention can be performed by measuring the fluorescence intensity, and the operation is extremely simple.
- the present invention provides a sample containing extremely low concentrations as described above.
- environmental hormones can be detected with high sensitivity and their operation is extremely easy, their contribution to the field of environmental protection and, in turn, to the maintenance of ecosystems is enormous.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00911341A EP1231468A4 (en) | 1999-10-14 | 2000-03-24 | METHOD OF DETECTING AN EXOGENOUS ENDOCRINE DISRUPTION CHEMICAL AGENT AND DETECTION APPARATUS |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP29303799A JP3483246B2 (ja) | 1999-10-14 | 1999-10-14 | 外因性内分泌撹乱物質の検出方法および検出装置 |
JP11/293037 | 1999-10-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001027619A1 true WO2001027619A1 (fr) | 2001-04-19 |
Family
ID=17789683
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/001813 WO2001027619A1 (fr) | 1999-10-14 | 2000-03-24 | Methode de detection d'un agent chimique exogene de perturbation endocrine et appareil de detection |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1231468A4 (ja) |
JP (1) | JP3483246B2 (ja) |
WO (1) | WO2001027619A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108845131A (zh) * | 2018-06-20 | 2018-11-20 | 广州质量监督检测研究院 | 检测双酚b的胶体金免疫层析检测卡及其制备方法和应用 |
CN114199838A (zh) * | 2021-11-19 | 2022-03-18 | 中国科学院生态环境研究中心 | 环境污染中环境雌激素干扰物的检测方法 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4593754B2 (ja) * | 2000-10-13 | 2010-12-08 | 一般財団法人 化学物質評価研究機構 | 化学物質の50%阻害濃度決定方法 |
JP4777983B2 (ja) * | 2005-06-14 | 2011-09-21 | 京都電子工業株式会社 | 環境試料スクリーニング測定方法及び装置 |
CN103175973B (zh) * | 2013-02-26 | 2015-05-13 | 首都医科大学 | 甘丙肽在制备女性抑郁症检测工具中的应用 |
WO2017053839A1 (en) | 2015-09-25 | 2017-03-30 | Iontox, Llc | Endocrine disruptor field tester |
CN109900665B (zh) * | 2019-02-27 | 2021-04-30 | 山东省科学院海洋仪器仪表研究所 | 一种分子印迹选择荧光猝灭法测量水体中ddt的方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0643163A (ja) * | 1991-02-12 | 1994-02-18 | Olympus Optical Co Ltd | 酵素免疫自動測定方法 |
JPH06265550A (ja) * | 1993-03-16 | 1994-09-22 | Kyowa Medex Co Ltd | 磁性担体粒子を用いた免疫測定方法 |
JPH09273993A (ja) * | 1996-04-03 | 1997-10-21 | Matsushita Electric Ind Co Ltd | 溶液測定用セルを用いた連続蛍光分析方法 |
-
1999
- 1999-10-14 JP JP29303799A patent/JP3483246B2/ja not_active Expired - Fee Related
-
2000
- 2000-03-24 WO PCT/JP2000/001813 patent/WO2001027619A1/ja not_active Application Discontinuation
- 2000-03-24 EP EP00911341A patent/EP1231468A4/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0643163A (ja) * | 1991-02-12 | 1994-02-18 | Olympus Optical Co Ltd | 酵素免疫自動測定方法 |
JPH06265550A (ja) * | 1993-03-16 | 1994-09-22 | Kyowa Medex Co Ltd | 磁性担体粒子を用いた免疫測定方法 |
JPH09273993A (ja) * | 1996-04-03 | 1997-10-21 | Matsushita Electric Ind Co Ltd | 溶液測定用セルを用いた連続蛍光分析方法 |
Non-Patent Citations (2)
Title |
---|
RANDALL BOLGER ET AL.: "Rapid Screening of Environmental Chemicals for Estrogen Receptor Binding Capacity", ENVIRONMENTAL HEALTH PERSPECTIVES, vol. 106, no. 9, September 1998 (1998-09-01), USA, pages 551 - 557, XP002929042 * |
See also references of EP1231468A4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108845131A (zh) * | 2018-06-20 | 2018-11-20 | 广州质量监督检测研究院 | 检测双酚b的胶体金免疫层析检测卡及其制备方法和应用 |
CN114199838A (zh) * | 2021-11-19 | 2022-03-18 | 中国科学院生态环境研究中心 | 环境污染中环境雌激素干扰物的检测方法 |
CN114199838B (zh) * | 2021-11-19 | 2024-02-23 | 中国科学院生态环境研究中心 | 环境污染中环境雌激素干扰物的检测方法 |
Also Published As
Publication number | Publication date |
---|---|
JP2001116753A (ja) | 2001-04-27 |
EP1231468A4 (en) | 2005-05-25 |
JP3483246B2 (ja) | 2004-01-06 |
EP1231468A1 (en) | 2002-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8859265B2 (en) | Lateral flow immunoassay device with a more rapid and accurate test result | |
US4923819A (en) | Time-resolved fluorescence immunoassay | |
US11371987B2 (en) | Method of amplifying detection light using light-reflecting material, in immunochromatography | |
JP3021038B2 (ja) | 標識技術を用いた複数分析物の検出または定量 | |
US20170234866A1 (en) | Multiplexed lateral flow assay | |
AU2001262994A1 (en) | Improvements to the fluorescent polymer-QTL approach to biosensing | |
WO2017138946A1 (en) | Multiplexed lateral flow assay | |
JP2024074809A (ja) | 側方流動アッセイのシグナルを増幅させるシステム、装置および方法 | |
JP2004514907A (ja) | 生物分析的アッセイ | |
CN114910638A (zh) | 一种无基质效应的均相免疫检测分析方法 | |
JP5006459B1 (ja) | 標識用複合粒子 | |
US20200209230A1 (en) | Methods and compositions relating to small molecule analyte assays | |
CA2106339A1 (en) | Separation method | |
WO2001027619A1 (fr) | Methode de detection d'un agent chimique exogene de perturbation endocrine et appareil de detection | |
WO2015129384A1 (ja) | 糖鎖を含む標的物質の検出用試薬、検出方法、および糖鎖を含む標的物質を検出するために用いられる担体ならびにその製造方法 | |
PL173049B1 (pl) | Sposób mierzenia stężenia i/lub względnej zawartości swoistej immunoglobuliny w próbce | |
Attiya et al. | Affinity protection chromatography for efficient labeling of antibodies for use in affinity capillary electrophoresis | |
US5202269A (en) | Method for immunochemical determination of hapten | |
CN114486822A (zh) | 一种用fret技术检测抗原抗体相互作用的方法 | |
KR101726181B1 (ko) | 면역크로마토그래피 분석용 디바이스 | |
JP2002189027A (ja) | 免疫検出方法 | |
JP2574068B2 (ja) | 診断用アッセイ系 | |
JPH02502122A (ja) | 液体中のリガンドを検出及び定量する方法 | |
JP2004144687A (ja) | 物質の測定方法 | |
US20240272153A1 (en) | Method for re-using a test solid surface in a biochemical assay |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2000911341 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10110445 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2000911341 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000911341 Country of ref document: EP |